Thalidomide as an emerging immunotherapeutic agent (Q33774204)

29 July 2017

1 reference

title

Thalidomide as an emerging immunotherapeutic agent (English)

1 reference

29 July 2017

0 references

1 reference

Marriott JB

1

1 reference

PubMed ID

10562702

29 July 2017

Muller G

series ordinal

2

1 reference

PubMed ID

10562702

29 July 2017

Dalgleish AG

series ordinal

3

1 reference

29 July 2017

1 December 1999

1 reference

29 July 2017

1 reference

29 July 2017

20

1 reference

29 July 2017

12

1 reference

29 July 2017

538-540

1 reference

Neuropathy after intake of thalidomide (distaval)

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

THALIDOMIDE AND CONGENITAL ABNORMALITIES

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

The Influence of Thalidomide on the Clinical and Immunologic Manifestation of Erythema Nodosum Leprosum

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide for graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide for the treatment of chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide: rationale for renewed use in immunological disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

The treatment of microsporidial diarrhoea with thalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide inhibits the replication of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Taming TNF: strategies to restrain this proinflammatory cytokine

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Augmentation by phthalimides of phorbol ester-induced expression of tumor necrosis factor alpha message

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide's chirality

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Thalidomide analogs and PDE4 inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901531-5

7 January 2021

10.1016/S0167-5699(99)01531-5

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10562702